Pipeline

OUR PIPELINE AND PROGRAMS

UNMATCHED BREAKTHROUGH
COUR’s CNP-101 for celiac disease, partnered with Takeda, is the first therapy to induce antigen-specific immune tolerance in any autoimmune disease in humans.

VALIDATED PLATFORM WITH BROAD APPLICATIONS
COUR’s Nanoparticle Platform can be employed to induce disease-specific tolerance for the treatment of a myriad of autoimmune and allergic diseases by changing the antigen or allergen that is encapsulated within the nanoparticle.

COUR is advancing its pipeline of first-in-class therapies for immune-mediated disease.

CNP-101/TAK-101 (Celiac Disease) CNP-201 (Peanut Allergy) CNP-104 (Primary Biliary Cholangitis) CNP-T1D (Type 1 Diabetes) CNP-MYG (Myasthenia Gravis) CNP-ITP (Immune Thrombocytopenia Purpura) View Full